PDL Biopharma discloses hostile bid to acquire Neos for $10.25/share; proposal later terminated
Executive Summary
PDL BioPharma Inc. made public its launch of a hostile bid to acquire Nasdaq-traded Neos Therapeutics Inc. (modified-release oral drug delivery platform) for $10.25 in cash per share (a 32% premium to the previous 10-day closing average to the October announcement date).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Controlled Release
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice